Literature DB >> 11855561

Porphyria cutanea tarda: multiplicity of risk factors including HFE mutations, hepatitis C, and inherited uroporphyrinogen decarboxylase deficiency.

Norman G Egger1, Douglas E Goeger, Deborah A Payne, Emil P Miskovsky, Steven A Weinman, Karl E Anderson.   

Abstract

The coexistence of factors considered to contribute to development of porphyria cutanea tarda was studied in 39 consecutive patients. Highly prevalent factors were alcohol intake in 79%, smoking in 86%, hepatitis C virus infection in 74%, estrogen use in 73% of 11 females, and at least one mutation in the HFE (hereditary hemochromatosis) gene in 65%. The C282Y mutation was found in 29%, H63D in 47%, and S65C in 0%. HFE genotypes included C282Y/C282Y in 9%, H63D/H63D in 9%, C282Y/H63D in 12%, C282Y/wild type in 9%, and H63D/wild type in 26%. Less prevalent were HIV infection in 15% (or 25% of those tested, N = 24) and erythrocyte uroporphyrinogen decarboxylase deficiency, which distinguishes familial (type 2) from "sporadic" (type 1) porphyria cutanea tarda, in 19%. Multiple contributing factors coexisted in both types 1 and 2, with 92% of all patients having three or more factors. These observations indicate that this porphyria is multifactorial in the individual patient, and therefore is seldom attributable to a single identifiable cause. Profiling for all potentially contributing factors is important for individualizing management.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11855561     DOI: 10.1023/a:1013746828074

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  61 in total

1.  Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda.

Authors:  Z J Bulaj; J D Phillips; R S Ajioka; M R Franklin; L M Griffen; D J Guinee; C Q Edwards; J P Kushner
Journal:  Blood       Date:  2000-03-01       Impact factor: 22.113

2.  HFE mutations analysis in 711 hemochromatosis probands: evidence for S65C implication in mild form of hemochromatosis.

Authors:  C Mura; O Raguenes; C Férec
Journal:  Blood       Date:  1999-04-15       Impact factor: 22.113

3.  Ascorbic acid deficiency in porphyria cutanea tarda.

Authors:  P R Sinclair; N Gorman; S I Shedlofsky; C P Honsinger; J F Sinclair; M R Karagas; K E Anderson
Journal:  J Lab Clin Med       Date:  1997-08

4.  Porphyria cutanea tarda and hepatitis C virus: a case-control study and meta-analysis of the literature.

Authors:  T Y Chuang; R Brashear; C Lewis
Journal:  J Am Acad Dermatol       Date:  1999-07       Impact factor: 11.527

5.  Hepatitis C virus and porphyria cutanea tarda: evidence of a strong association.

Authors:  S Fargion; A Piperno; M D Cappellini; M Sampietro; A L Fracanzani; R Romano; R Caldarelli; R Marcelli; L Vecchi; G Fiorelli
Journal:  Hepatology       Date:  1992-12       Impact factor: 17.425

6.  Hepatocellular carcinoma in porphyria cutanea tarda: frequency and factors related to its occurrence.

Authors:  P D Siersema; F J ten Kate; P G Mulder; J H Wilson
Journal:  Liver       Date:  1992-04

7.  Ascorbic acid inhibition of cytochrome P450-catalyzed uroporphyrin accumulation.

Authors:  P R Sinclair; N Gorman; H S Walton; W J Bement; J M Jacobs; J F Sinclair
Journal:  Arch Biochem Biophys       Date:  1993-08-01       Impact factor: 4.013

8.  Porphyria cutanea tarda associated with human immunodeficiency virus infection.

Authors:  C Drobacheff; C Derancourt; H Van Landuyt; D Devred; B de Wazieres; B Cribier; D Rey; J M Lang; C Grosieux; B Kalis; R Laurent
Journal:  Eur J Dermatol       Date:  1998 Oct-Nov       Impact factor: 3.328

9.  Oxidation of uroporphyrinogens by hydroxyl radicals. Evidence for nonporphyrin products as potential inhibitors of uroporphyrinogen decarboxylase.

Authors:  J E Francis; A G Smith
Journal:  FEBS Lett       Date:  1988-06-20       Impact factor: 4.124

Review 10.  Human immunodeficiency virus infection and porphyria cutanea tarda: coexistence of risk factors or causative association?

Authors:  F McAlister; K McClean; P G Hamilton; S Houston
Journal:  Clin Infect Dis       Date:  1995-02       Impact factor: 9.079

View more
  15 in total

1.  Porphyria cutanea tarda and hepatoerythropoietic porphyria: Identification of 19 novel uroporphyrinogen III decarboxylase mutations.

Authors:  Yedidyah Weiss; Brenden Chen; Makiko Yasuda; Irina Nazarenko; Karl E Anderson; Robert J Desnick
Journal:  Mol Genet Metab       Date:  2018-11-28       Impact factor: 4.797

Review 2.  Heme biosynthesis and the porphyrias.

Authors:  John D Phillips
Journal:  Mol Genet Metab       Date:  2019-04-22       Impact factor: 4.797

Review 3.  Porphyria Diagnostics-Part 1: A Brief Overview of the Porphyrias.

Authors:  Vaithamanithi-Mudumbai Sadagopa Ramanujam; Karl Elmo Anderson
Journal:  Curr Protoc Hum Genet       Date:  2015-07-01

Review 4.  Hepatitis C, porphyria cutanea tarda and liver iron: an update.

Authors:  F Ryan Caballes; Hossein Sendi; Herbert L Bonkovsky
Journal:  Liver Int       Date:  2012-04-17       Impact factor: 5.828

Review 5.  Hepatitis C virus-associated extrahepatic manifestations: a review.

Authors:  Damien Sène; Nicolas Limal; Patrice Cacoub
Journal:  Metab Brain Dis       Date:  2004-12       Impact factor: 3.584

6.  CYP1A2*1F and GSTM1 alleles are associated with susceptibility to porphyria cutanea tarda.

Authors:  Jeffrey K Wickliffe; Sherif Z Abdel-Rahman; Chul Lee; Csilla Kormos-Hallberg; Gagan Sood; Catherine M Rondelli; James J Grady; Robert J Desnick; Karl E Anderson
Journal:  Mol Med       Date:  2010-10-15       Impact factor: 6.354

7.  Associations among behavior-related susceptibility factors in porphyria cutanea tarda.

Authors:  Sajid Jalil; James J Grady; Chul Lee; Karl E Anderson
Journal:  Clin Gastroenterol Hepatol       Date:  2009-11-27       Impact factor: 11.382

Review 8.  Severe radiation therapy-related soft tissue toxicity in a patient with porphyria cutanea tarda: a literature review.

Authors:  G Brandon Gunn; Karl E Anderson; Abhilasha J Patel; Juan Gallegos; Csilla Kormos Hallberg; Gagan Sood; Sandra S Hatch; Giuseppe Sanguineti
Journal:  Head Neck       Date:  2010-08       Impact factor: 3.147

9.  Low-dose hydroxychloroquine is as effective as phlebotomy in treatment of patients with porphyria cutanea tarda.

Authors:  Ashwani K Singal; Csilla Kormos-Hallberg; Chul Lee; Vaithamanithi M Sadagoparamanujam; James J Grady; Daniel H Freeman; Karl E Anderson
Journal:  Clin Gastroenterol Hepatol       Date:  2012-09-14       Impact factor: 11.382

10.  An unhappy triad: hemochromatosis, porphyria cutanea tarda and hepatocellular carcinoma-a case report.

Authors:  Martina-T Mogl; Andreas Pascher; Sabine-J Presser; Michael Schwabe; Peter Neuhaus; Natascha-C Nuessler
Journal:  World J Gastroenterol       Date:  2007-04-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.